AIDS 2024

AIDS 2024
July 22-26, 2024
Munich, Germany

25th International AIDS Conference.

Explore more information for Gilead HIV / AIDS therapies
Results (16)

(Graphical Summary) TWICE-YEARLY LENACAPAVIR OR DAILY ORAL F/TAF FOR HIV PREVENTION IN CISGENDER WOMEN: INTERIM ANALYSIS RESULTS FROM THE PURPOSE 1 STUDY

EFFICACY AND SAFETY OF BICTEGRAVIR PLUS LENACAPAVIR: 48-WEEK OUTCOMES IN VIROLOGICALLY SUPPRESSED PEOPLE WITH HIV-1 ON COMPLEX ART REGIMENS AT BASELINE

GS-8588, A NOVEL ENVELOPE-TARGETING BISPECIFIC T-CELL ENGAGER FOR HIV CURE

REAL-WORLD ADHERENCE OF HIV-1 ORAL PREP REGIMENS IN THE UNITED STATES: A GROUP-BASED TRAJECTORY MODELING APPROACH

ASSESSMENT OF LONGITUDINAL CHANGES IN RENAL FUNCTION OF HIV-1 ORAL PREP USERS USING REAL-WORLD DATA IN THE UNITED STATES

CENTERING COMMUNITY LEADERSHIP WITH PURPOSE: INCLUSION OF ADOLESCENTS, CISWOMEN, AND PREGNANT AND LACTATING INDIVIDUALS IN A PHASE 3 CLINICAL TRIAL EVALUATING LENACAPAVIR (LEN) AND EMTRICITABINE/TENOFOVIR ALAFENAMIDE (F/TAF) FOR PREP

NONCLINICAL PROFILE OF GS-4182, A ONCE-WEEKLY ORAL PRODRUG OF THE HIV-1 CAPSID INHIBITOR LENACAPAVIR IN CLINICAL DEVELOPMENT

NONCLINICAL PHARMACOLOGY PROFILE OF GS-1720, A NOVEL HIGHLY POTENT ONCE-WEEKLY ORAL HIV-1 INSTI INHIBITOR IN CLINICAL DEVELOPMENT

RESISTANCE ANALYSES DURING TREATMENT OF LENACAPAVIR WITH BROADLY NEUTRALIZING ANTIBODIES IN PEOPLE WITH HIV

EXPERIENCES AND QUALITY OF LIFE WITH LONG-ACTING LENACAPAVIR FROM PEOPLE WITH MULTIDRUG-RESISTANT HIV-1 ENROLLED IN THE PHASE 2/3 CAPELLA STUDY

TWICE-YEARLY LENACAPAVIR OR DAILY ORAL F/TAF FOR HIV PREVENTION IN CISGENDER WOMEN: INTERIM ANALYSIS RESULTS FROM THE PURPOSE 1 STUDY

SAFETY AND PK PROFILE OF SINGLE AND MULTIPLE ASCENDING DOSES OF GS 4182, AN ORAL PRODRUG OF LENACAPAVIR, IN PARTICIPANTS WITHOUT HIV-1

PHASE 1A PK AND SAFETY OF SINGLE ASCENDING DOSES OF GS-1720 IN HEALTHY PARTICIPANTS SUPPORTS ORAL WEEKLY ADMINISTRATION AND PHASE 1B DOSE SELECTION

INJECTION SITE REACTIONS WITH SUBCUTANEOUS LENACAPAVIR ADMINISTRATION AT ALTERNATE INJECTION SITES

SWITCHING TO B/F/TAF IN A REAL-WORLD COHORT OF OLDER PEOPLE WITH HIV AND HIGH BURDEN OF NON-AIDS-RELATED COMORBIDITIES

EFFICACY AND SAFETY OF B/F/TAF IN HISPANIC/LATINE ADULTS WITH HIV-1 INITIATING FIRST-LINE THERAPY: 5-YEAR FOLLOW-UP FROM TWO PHASE 3 STUDIES